Left ventricular assist devices as destination therapy for end-stage heart failure

Because of progressive diabetes with end organ damage (retinopathy) and his advanced age, he is not considered an ideal transplant candidate. [...]the REMATCH trial was conducted with the first generation HeartMate device; subsequent advances in VAD technology have incorporated changes specifically...

Ausführliche Beschreibung